1. Home
  2. GLW vs ALNY Comparison

GLW vs ALNY Comparison

Compare GLW & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLW
  • ALNY
  • Stock Information
  • Founded
  • GLW 1851
  • ALNY 2002
  • Country
  • GLW United States
  • ALNY United States
  • Employees
  • GLW N/A
  • ALNY N/A
  • Industry
  • GLW Telecommunications Equipment
  • ALNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • GLW Industrials
  • ALNY Health Care
  • Exchange
  • GLW Nasdaq
  • ALNY Nasdaq
  • Market Cap
  • GLW 73.2B
  • ALNY 60.7B
  • IPO Year
  • GLW N/A
  • ALNY 2004
  • Fundamental
  • Price
  • GLW $88.72
  • ALNY $456.27
  • Analyst Decision
  • GLW Strong Buy
  • ALNY Strong Buy
  • Analyst Count
  • GLW 12
  • ALNY 27
  • Target Price
  • GLW $87.00
  • ALNY $483.89
  • AVG Volume (30 Days)
  • GLW 7.1M
  • ALNY 1.1M
  • Earning Date
  • GLW 10-28-2025
  • ALNY 10-30-2025
  • Dividend Yield
  • GLW 1.26%
  • ALNY N/A
  • EPS Growth
  • GLW 751.19
  • ALNY N/A
  • EPS
  • GLW 1.56
  • ALNY 0.33
  • Revenue
  • GLW $14,915,000,000.00
  • ALNY $3,210,070,000.00
  • Revenue This Year
  • GLW $25.83
  • ALNY $65.55
  • Revenue Next Year
  • GLW $11.41
  • ALNY $41.48
  • P/E Ratio
  • GLW $57.10
  • ALNY $1,372.54
  • Revenue Growth
  • GLW 18.27
  • ALNY 53.24
  • 52 Week Low
  • GLW $37.31
  • ALNY $205.87
  • 52 Week High
  • GLW $92.57
  • ALNY $495.55
  • Technical
  • Relative Strength Index (RSI)
  • GLW 57.24
  • ALNY 51.88
  • Support Level
  • GLW $83.33
  • ALNY $417.00
  • Resistance Level
  • GLW $88.82
  • ALNY $445.49
  • Average True Range (ATR)
  • GLW 2.73
  • ALNY 16.65
  • MACD
  • GLW -0.38
  • ALNY -1.14
  • Stochastic Oscillator
  • GLW 61.15
  • ALNY 58.85

About GLW Corning Incorporated

Corning is a leader in materials science, specializing in the production of glass, ceramics, and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: